GlycoMantra, a University of Maryland, Baltimore startup, received a $3.7 million SBIR Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases. The funding aims to advance the development of therapeutics for metastatic castration-resistant prostate cancer, liver fibrosis and type 2 diabetes.
Irazu Oncology, a biotech company using a platform developed by University of Maryland, Baltimore (UMB) researchers for cancer vaccine development, has reportedly secured $2.6 million in debt from an undisclosed source, as reported by citybiz+. Claire D. Murphy, director of strategic marketing for UMB’s Office of Research and Development, told Technical.ly that the company raised $1.8 million in a preliminarily closed seed round as of Dec. 14.
Elixirgen Therapeutics, a biotech firm dedicated to developing therapies for genetic diseases and vaccines, has raised nearly $7 million, according to a Securities and Exchange Commission (SEC) filing. The company did not immediately confirm its plans for the raise.
READ FULL ARTICLE HERE
